Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Aug;69(2):231–239.

Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

A Ranki 1, S H Weiss 1, S L Valle 1, J Antonen 1, K J Krohn 1
PMCID: PMC1542406  PMID: 3652531

Abstract

Sequential serum samples, collected over a 2-3 year follow-up period, of 28 HIV-infected individuals were tested for the presence of neutralizing antibodies against one HIV isolate, HTLV-IIIB, and titrated, by Western blotting, against different HTLV-III specific proteins. Neutralizing antibodies were found in 66% of the samples tested and highest neutralization titres observed in cases with lymphadenopathy syndrome. Antibody titres against the viral proteins also seemed to be highest in cases with LAS. Neutralization titres correlated well with antibodies to envelope glycoproteins gp41 and gp120 and to one of the core proteins, p17. An increase in neutralization titre during the follow-up period was associated with a stable clinical course. Furthermore, the occurrence of antibodies directed against the external envelope glycoprotein (gp120) in the initial serum sample correlated well with a stable clinical course. The results suggest that neutralizing activity in the serum, particularly that evoked against gp120, may have some prognostic significance, and that several distinct antigenic epitopes on the virus may be a target for neutralizing antibodies.

Full text

PDF
233

Images in this article

235Fig. 2
on p.235

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. S., Coligan J. E., Barin F., McLane M. F., Sodroski J. G., Rosen C. A., Haseltine W. A., Lee T. H., Essex M. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science. 1985 May 31;228(4703):1091–1094. doi: 10.1126/science.2986290. [DOI] [PubMed] [Google Scholar]
  2. Barin F., McLane M. F., Allan J. S., Lee T. H., Groopman J. E., Essex M. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985 May 31;228(4703):1094–1096. doi: 10.1126/science.2986291. [DOI] [PubMed] [Google Scholar]
  3. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. doi: 10.1002/j.1460-2075.1986.tb04607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faulkner-Valle G. P., De Rossi A., Dalla Gassa O., Chieco-Bianchi L. LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals. Tumori. 1986 Jun 30;72(3):219–224. doi: 10.1177/030089168607200301. [DOI] [PubMed] [Google Scholar]
  5. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986 Jul 11;233(4760):215–219. doi: 10.1126/science.3014648. [DOI] [PubMed] [Google Scholar]
  6. Gelderblom H. R., Hausmann E. H., Ozel M., Pauli G., Koch M. A. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology. 1987 Jan;156(1):171–176. doi: 10.1016/0042-6822(87)90449-1. [DOI] [PubMed] [Google Scholar]
  7. Gelderblom H. R., Reupke H., Pauli G. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis? Lancet. 1985 Nov 2;2(8462):1016–1017. doi: 10.1016/s0140-6736(85)90570-7. [DOI] [PubMed] [Google Scholar]
  8. Ho D. D., Rota T. R., Hirsch M. S. Antibody to lymphadenopathy-associated virus in AIDS. N Engl J Med. 1985 Mar 7;312(10):649–650. doi: 10.1056/NEJM198503073121015. [DOI] [PubMed] [Google Scholar]
  9. Kennedy-Stoskopf S., Narayan O. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence. J Virol. 1986 Jul;59(1):37–44. doi: 10.1128/jvi.59.1.37-44.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koenig S., Gendelman H. E., Orenstein J. M., Dal Canto M. C., Pezeshkpour G. H., Yungbluth M., Janotta F., Aksamit A., Martin M. A., Fauci A. S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986 Sep 5;233(4768):1089–1093. doi: 10.1126/science.3016903. [DOI] [PubMed] [Google Scholar]
  11. Krohn K., Ranki A., Antonen J., Valle S. L., Suni J., Vaheri A., Saxinger C., Gallo R. C. Immune functions in homosexual men with antibodies to HTLV-III in Finland. Clin Exp Immunol. 1985 Apr;60(1):17–24. [PMC free article] [PubMed] [Google Scholar]
  12. McDougal J. S., Kennedy M. S., Sligh J. M., Cort S. P., Mawle A., Nicholson J. K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science. 1986 Jan 24;231(4736):382–385. doi: 10.1126/science.3001934. [DOI] [PubMed] [Google Scholar]
  13. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mitsuya H., Guo H. G., Cossman J., Megson M., Reitz M. S., Jr, Broder S. Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science. 1984 Sep 28;225(4669):1484–1486. doi: 10.1126/science.6206569. [DOI] [PubMed] [Google Scholar]
  15. Modrow S., Hahn B. H., Shaw G. M., Gallo R. C., Wong-Staal F., Wolf H. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol. 1987 Feb;61(2):570–578. doi: 10.1128/jvi.61.2.570-578.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rasheed S., Norman G. L., Gill P. S., Meyer P. R., Cheng L., Levine A. M. Virus-neutralizing activity, serologic heterogeneity, and retrovirus isolation from homosexual men in the Los Angeles area. Virology. 1986 Apr 15;150(1):1–9. doi: 10.1016/0042-6822(86)90260-6. [DOI] [PubMed] [Google Scholar]
  17. Robert-Guroff M., Brown M., Gallo R. C. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 1985 Jul 4;316(6023):72–74. doi: 10.1038/316072a0. [DOI] [PubMed] [Google Scholar]
  18. Robey W. G., Arthur L. O., Matthews T. J., Langlois A., Copeland T. D., Lerche N. W., Oroszlan S., Bolognesi D. P., Gilden R. V., Fischinger P. J. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7023–7027. doi: 10.1073/pnas.83.18.7023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sarin P. S., Sun D. K., Thornton A. H., Naylor P. H., Goldstein A. L. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1. Science. 1986 May 30;232(4754):1135–1137. doi: 10.1126/science.3010464. [DOI] [PubMed] [Google Scholar]
  20. Sarngadharan M. G., Popovic M., Bruch L., Schüpbach J., Gallo R. C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984 May 4;224(4648):506–508. doi: 10.1126/science.6324345. [DOI] [PubMed] [Google Scholar]
  21. Saxinger C., Gallo R. C. Methods in laboratory investigation. Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of human t cell leukemia-lymphoma virus. Lab Invest. 1983 Sep;49(3):371–377. [PubMed] [Google Scholar]
  22. Starcich B. R., Hahn B. H., Shaw G. M., McNeely P. D., Modrow S., Wolf H., Parks E. S., Parks W. P., Josephs S. F., Gallo R. C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. doi: 10.1016/0092-8674(86)90778-6. [DOI] [PubMed] [Google Scholar]
  23. Valle S. L., Saxinger C., Ranki A., Antonen J., Suni J., Lähdevirta J., Krohn K. Diversity of clinical spectrum of HTLV-III infection. Lancet. 1985 Feb 9;1(8424):301–304. doi: 10.1016/s0140-6736(85)91080-3. [DOI] [PubMed] [Google Scholar]
  24. Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985 Jul 4;316(6023):69–72. doi: 10.1038/316069a0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES